Chapter 431 - 260: Milestone! Fengmu Tiada’s Clinical Debut
Chapter 431: Chapter 260: Milestone! Fengmu Tiada’s Clinical Debut
"Understood. I guarantee I’ll complete the mission."
Zhang Heng had been waiting a long time for this day, to finally be able to perform this surgery.
...
...
The operating room of the Hepatic Tumor Surgery department.
Wu Ting was leading his team to perform surgery on Professor Long for mid-to-late-stage primary liver cancer caused by Hepatitis B.
Wu Ting had also waited a long time for this day.
In addition to the surgical team, the new drug research and development team also made an appearance. Jia Jun, as their representative, participated in the press conference before the surgery began.
The various experts and professors from the Central Region whom Wu Ting had invited all showed up, giving him a great deal of face!
Due to the distance, Professor Liang Ang from Lin Province Pinfan Hospital sent his well wishes via video. He also planned to observe the surgery later through a live online broadcast.
Dean Liu Rong of Qinghe City Jin Country General Hospital also sent a video of his well wishes before the surgery. He expressed his keen interest and would also be observing the procedure live.
In the guest seating area, Director Fu, Director Ma, Dean Chen, Director Jin, Director Shen, and more—the top surgical blades of Jin Province—were all gathered together.
Huo Yun, Qin Donglai, Cai Qi, and Dean Tang from Fan City First Hospital were all participating as hosts for this event.
Reporters from Fan City Television, the publicity department from Wu’s Pharmaceutical Company, and the team from Jin Pharmaceutical Group were also involved in the promotion and publicity for the event.
The leadership from Fan City University Medical College—the two brothers, Vice Dean Duan and Director Duan of the Medical Experiment Center—also made an appearance!
Far away in the Southern Country, Professor Lin Ning’s team also expressed that they would be following the surgery online.
After the press conference concluded, where it was announced that Fengmu Tiada had officially entered the clinical trial phase, Wu Ting led his team into the operating room.
The large screen at the press conference venue was now connected to a feed from the operating room.
Wu Ting had defined this surgery as: "Phase Three of the Complete Radical Cure Therapy for Hepatitis B Primary Liver Cancer—targeting patients with mid-to-late-stage liver cancer that has already progressed to the late stage, who have lost the opportunity for complete surgical resection, and can only resort to treatments like interventional therapy, chemotherapy, radiotherapy, radiofrequency ablation, biological therapy, or even Liver Transplantation!"
Inside the operating room, before officially beginning the Phase Three treatment, Wu Ting once again showcased the latest version of the WD large model, laboratory edition!
Although a resection was not required, this 3D imaging technology could still be used to provide an auxiliary diagnosis and a detailed exploration of the lesion.
After the WD large model, lab edition, was activated, it connected to the latest liver cancer database. Under the synthesis of various auxiliary technologies, a clear and detailed 3D image of the patient’s liver appeared on the screen.
This latest version of the database added comparisons with similar cases, classifications of typical cases, and a trial version of various detailed precautions and operational standards!
As they looked at the information presented by Wu Ting’s brand-new database, the top-tier experts and professors in the observation room were instantly stunned by his ambition and grand vision.
What Wu Ting was doing was nothing less than compiling and refining medical guidelines!
This was an incredible undertaking. The biggest challenge in creating medical guidelines is the sheer volume of clinical trial data!
The creation of a single set of guidelines is usually limited by time, manpower, and financial and material resources. Yet Wu Ting, through the widespread clinical adoption of the Wu’s Pharmaceutical Company’s system, was able to directly and effectively collect firsthand clinical data from top platforms across the country.
In addition to patient case data, there were also different teams, different Technicians, and different surgical procedures. This massive amount of information was integrated together. By using big data, artificial intelligence, and the large model’s millions-fold increase in efficiency for integration and statistics, the time and progress for writing clinical guidelines were drastically shortened.
This was a method of writing guidelines that no one had ever attempted before. By networking the Heaven and Earth Hospitals, it completely solved the problem of pooling collective wisdom and overcoming limitations. This was truly a remarkable innovation!
Director Fu, Dean Chen, Director Ma, and the others also realized the significance and value of what Wu Ting was doing.
This was only the first surgery of Phase Three. If Wu Ting really continued to push forward and completed the research for Phase Three, and even Phase Four, he would be integrating the entire medical system of Jin Country to complete a definitive radical cure for Hepatitis B primary liver cancer!
The hearts of the top experts began to pound with excitement.
Director Fu, Dean Chen, Director Ma, Director Jin, and the others exchanged glances and quickly reached a consensus: this was a monumental event.
As long as Wu Ting’s surgery was successful today, they would have to go to Qinghe City and find Scholar Zeng Jiu, the president of the Hepatobiliary and Pancreatic Surgery branch of the Medical Association. They needed to properly plan and strategize for Wu Ting’s grand plan.
This was no longer a matter for Wu Ting alone, nor was it something the Hepatic Tumor Surgery department at Fan City First Hospital could accomplish by itself. It was a revolutionary event for the entire field of hepatic tumor surgery within Jin Country’s medical community.
It was time for the top leaders, the heavyweights of the entire system, to step forward!
As the "ceiling" of Jin Country’s hepatic tumor field, Dean Chen had another terrifying thought: what if they organized the experts from the Hepatobiliary and Pancreatic Surgery branch of the Medical Association and established a special hepatic tumor group centered around Wu Ting!
A national hepatic tumor group, tasked with conquering Hepatitis B primary liver cancer and creating the clinical guidelines for its complete and radical cure!
Back in the operating room, after showcasing the database and the WD large model, lab edition—one of the core achievements of Phase Two—Wu Ting began the official surgery, which was also the first human clinical trial for Fengmu Tiada!